Clinical trials
Completed Peanut Hypersensitivity trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
67 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 67 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of North Carolina, Chapel Hill | 12 |
| Aimmune Therapeutics, Inc. | 8 |
| DBV Technologies | 8 |
| Johns Hopkins University | 5 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| Astellas Pharma Global Development, Inc. | 2 |
| Massachusetts General Hospital | 2 |
| Regeneron Pharmaceuticals | 2 |
| Stanford University | 2 |
| ALK-Abelló A/S | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peanut Hypersensitivity | 67 |
| Food Hypersensitivity | 32 |
| Hypersensitivity | 21 |
| Hypersensitivity, Immediate | 9 |
| Anaphylaxis | 4 |
| Nut Hypersensitivity | 4 |
| Egg Hypersensitivity | 3 |
| Milk Hypersensitivity | 3 |
| Immune System Diseases | 2 |
| Anxiety Disorders | 1 |
Trials
Showing 1 to 25 of 67. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.